07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

Jublia efinaconazole regulatory update

Kaken's marketing partner Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Montreal, Quebec) said FDA approved an NDA for Jublia efinaconazole to treat onychomycosis of the toenails. The company said it plans to launch the product "within...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Anacor, Valeant Pharmaceuticals infectious, dermatology news

Valeant agreed to pay Anacor $142.5 million to settle all existing and future claims between the companies related to contracts with Dow Pharmaceutical Sciences Inc. and Medicis Pharmaceutical Corp. The payment will cover $100 million...
07:00 , Oct 21, 2013 |  BC Week In Review  |  Company News

Anacor, Valeant Pharmaceuticals infectious news

An arbitrator awarded Anacor $100 million in damages as part of a contract dispute with Valeant. The dispute covers a 2004 deal between Anacor and Dow Pharmaceutical Sciences Inc. , under which Dow was providing...
07:00 , Oct 21, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Alimera Science Inc. (NASDAQ:ALIM) fell $0.23 to $2.48 on Friday after FDA issued a complete response letter for an NDA for Iluvien fluocinolone acetonide intravitreal implant to treat diabetic macular edema. Alimera said...
00:29 , Oct 19, 2013 |  BC Extra  |  Company News

Anacor jumps on damages award in contract dispute

Anacor Pharmaceuticals Inc. (NASDAQ:ANAC) gained $3.06 (28%) to $13.83 on Friday after announcing that an arbitrator awarded the company $100 million in damages as part of a contract dispute with Valeant Pharmaceuticals International Inc. (TSX:VRX;...
07:00 , Oct 7, 2013 |  BC Week In Review  |  Clinical News

Jublia efinaconazole regulatory update

Marketing partner Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Montreal, Quebec) said Health Canada approved an NDS for Jublia efinaconazole to treat mild to moderate onychomycosis. Valeant said it has not set a launch date. Canada...
07:00 , Jun 3, 2013 |  BC Week In Review  |  Clinical News

Efinaconazole regulatory update

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX, Mississauga, Ontario) said it received a complete response letter from FDA for an NDA for efinaconazole to treat onychomycosis. The company said FDA's questions pertain to CMC-related areas of...
07:00 , May 20, 2013 |  BC Week In Review  |  Company News

Anacor, Valeant Pharmaceuticals sales and marketing update

Valeant said it will not launch efinaconazole to treat onychomycosis until after its September arbitration hearing to resolve an inherited breach of contract dispute with Anacor. Valeant said it received notice last October that Anacor...
07:00 , Apr 1, 2013 |  BioCentury  |  Finance

2Q13 Financial Markets Preview: Manning the middle

Buysiders are being drawn to mid- and small cap biotechs with solid balance sheets and/or near-term inflection points going into 2Q13, a period that may be relatively quiet for some of the sector's largest names....
08:00 , Feb 4, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones ALK-Abello A/S (CSE:ALK-B) was up DKK26 to DKK441 on Friday after Merck & Co. Inc. (NYSE:MRK) said it submitted a BLA to FDA in January for its Grass Allergy Immunotherapy Tablet. Merck has...